who are we?

      About us

      Captor Therapeutics is a biopharmaceutical company focused on development of protein degradation drugs for cancer and autoimmune diseases, which have limited or no known treatment options.

      Targeted Protein Degradation (TPD) combats the therapeutic limits of small molecules with overcoming drug resistance and uncoupling their pharmacokinetics from pharmacodynamics. Breakthrough TPD technology allows degradation of virtually any intracellular protein including the so-called "undruggable proteome".

      Captor Therapeutics is a Swiss-Polish company. Captor GmbH entity operates in Basel, the pharma hub of Switzerland, providing excellent opportunities for business development, while our state-of-the-art laboratories are located in Wroclaw, Poland. Our integrated competencies and expertise in biology and chemistry allow us to perform all stages of early drug development.

      #undruggable proteome

      #targeted protein degradation

      #autoimmune diseases

      #high unmet medical needs


      We operate since 2017

      +150 years of a combined experience
      +44 M €
      for R&D projects
      +200 scientific publications and patents
      1100 m² of lab

      Captor Therapeutics employs more than 35 broad international experience!